UFP TECHNOLOGIES INC UFPT

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.

The consolidated financial statements of the Company include the accounts and results of operations of UFP Technologies, Inc. and its wholly owned subsidiaries, as well as its share of minority-owned equity investments. All significant intercompany balances and transactions have been eliminated in consolidation.

Last close 295.78 2026-10-23
Market cap $2.29B 2026-06-30 share count
52-week range 173.86 - 338.71

Valuation FY2025 figures against the last close

P/S3.8x
P/E33.8x
P/FCF24.9x
EV/EBITDA21.6x
Dividend yield—
Diluted EPS8.75

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $602.8M$504.4M$400.1M$353.8M$206.3M$179.4M$198.4M$190.5M$147.8M$146.1M
Cost of revenue $432.4M$357.7M$287.8M$263.5M$155.2M$134.7M$144.4M$142.1M$112.4M$111.5M
Gross profit $170.4M$146.7M$112.2M$90.3M$51.1M$44.7M$54.0M$48.3M$35.5M$34.6M
R&D $8.6M$10.4M$7.2M$9.3M$8.5M$8.2M$8.8M$10.5M$5.0M$1.3M
SG&A $77.4M$62.2M$50.9M$45.8M$29.5M$27.5M$29.3M$27.7M$23.7M$24.1M
Operating income $92.3M$80.9M$57.7M$55.4M$21.2M$16.7M$24.7M$19.6M$11.7M$12.2M
Interest expense $9.8M$8.1M$3.6M$2.8M$39.0K$83.0K$674.0K$1.3M$50.0K$69.0K
Pre-tax income $82.5M$73.0M$53.9M$52.7M$21.2M$16.3M$23.6M$18.4M$11.9M$12.3M
Income tax $14.2M$14.0M$9.0M$10.9M$5.3M$2.9M$3.9M$4.1M$2.6M$4.3M
Net income $68.3M$59.0M$44.9M$41.8M$15.9M$13.4M$19.8M$14.3M$9.2M$8.0M
EPS, basic 8.877.695.895.522.111.792.661.951.271.11
EPS, diluted 8.757.585.835.452.091.772.631.931.261.10
Shares, diluted (wtd. avg.) 7.8M7.8M7.7M7.7M7.6M7.6M7.5M7.4M7.3M7.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $20.3M$13.4M$5.3M$4.5M$11.1M$24.2M$3.7M$3.2M$38.0M$31.4M
Receivables $82.9M$84.7M$64.4M$55.1M$39.4M$26.4M$28.6M$28.3M$21.4M$21.2M
Inventory $86.9M$87.5M$70.2M$53.5M$33.4M$18.6M$18.3M$19.6M$12.9M$14.2M
Total current assets $201.0M$194.9M$144.6M$116.3M$87.3M$71.9M$53.2M$55.6M$75.1M$69.8M
Property, plant and equipment $79.1M$70.6M$62.1M$58.1M$56.6M$53.8M$56.7M$57.7M$53.7M$48.5M
Goodwill $197.4M$189.7M$113.3M$113.0M$107.9M$51.8M$51.8M$51.8M$7.3M$7.3M
Other intangibles $140.8M$144.3M$64.1M$68.4M$67.6M$19.7M$21.0M$22.2M—$318.0K
Total assets $655.1M$629.0M$404.1M$378.2M$334.1M$203.2M$188.8M$189.6M$138.2M$127.9M
Accounts payable $24.3M$24.3M$22.3M$20.0M$10.6M$4.1M$4.6M$6.8M$4.2M$4.0M
Short-term debt $12.5M$12.5M$4.0M$4.0M$4.0M$0—$2.9M—$856.0K
Total current liabilities $74.9M$76.3M$58.2M$56.0M$38.8M$15.1M$16.8M$20.7M$9.9M$9.6M
Long-term debt $123.0M$176.9M$28.0M$51.0M$71.0M$0—$22.3M—$856.0K
Total liabilities $231.2M$286.2M$118.0M$140.6M$139.7M$26.3M$26.8M$49.1M$14.5M$14.9M
Retained earnings $374.8M$306.5M$247.5M$202.6M$160.8M$144.9M$131.6M$111.8M$97.6M$88.4M
Total equity $423.9M$342.8M$286.1M$237.5M$194.4M$176.9M$162.0M$140.5M$123.7M$113.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $91.9M$66.6M$41.3M$17.7M$14.3M$25.0M$31.2M$21.3M$17.5M$9.3M
Depreciation and amortisation $19.1M$14.7M$11.4M$11.9M$8.4M$8.3M$8.2M$7.8M$5.6M$5.6M
Stock-based compensation $8.9M$6.8M$4.6M$3.2M$2.4M$1.8M$1.6M$1.2M$1.1M$1.1M
Capital expenditure —$9.7M$10.5M$13.8M$5.4M$4.4M$5.8M$5.4M$10.4M$7.2M
Investing cash flow -$27.6M-$210.2M-$10.5M$1.3M-$101.5M-$4.3M-$5.8M-$82.3M-$10.4M-$7.2M
Financing cash flow -$58.2M$152.4M-$30.0M-$25.9M$74.0M-$285.0K-$24.9M$26.3M-$475.0K-$559.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028710.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 200M 400M 600M 800M Revenue, FY2016: 146.1M Gross profit, FY2016: 34.6M Net income, FY2016: 8M Revenue, FY2017: 147.8M Gross profit, FY2017: 35.5M Net income, FY2017: 9.2M Revenue, FY2018: 190.5M Gross profit, FY2018: 48.3M Net income, FY2018: 14.3M Revenue, FY2019: 198.4M Gross profit, FY2019: 54M Net income, FY2019: 19.8M Revenue, FY2020: 179.4M Gross profit, FY2020: 44.7M Net income, FY2020: 13.4M Revenue, FY2021: 206.3M Gross profit, FY2021: 51.1M Net income, FY2021: 15.9M Revenue, FY2022: 353.8M Gross profit, FY2022: 90.3M Net income, FY2022: 41.8M Revenue, FY2023: 400.1M Gross profit, FY2023: 112.2M Net income, FY2023: 44.9M Revenue, FY2024: 504.4M Gross profit, FY2024: 146.7M Net income, FY2024: 59M Revenue, FY2025: 602.8M Gross profit, FY2025: 170.4M Net income, FY2025: 68.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $146.1M $147.8M $190.5M $198.4M $179.4M $206.3M $353.8M $400.1M $504.4M $602.8M
Gross profit $34.6M $35.5M $48.3M $54.0M $44.7M $51.1M $90.3M $112.2M $146.7M $170.4M
Net income $8.0M $9.2M $14.3M $19.8M $13.4M $15.9M $41.8M $44.9M $59.0M $68.3M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Cybersecurity incident A cybersecurity incident the company has determined to be material. Required since December 2023. Item 1.05

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%